REGENXBIO Inc.
RGNX
$6.72
$0.172.60%
| Weiss Ratings | RGNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | RGNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | RGNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.72 | |||
| Price History | RGNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 7.52% | |||
| 30-Day Total Return | -14.94% | |||
| 60-Day Total Return | -18.84% | |||
| 90-Day Total Return | -21.77% | |||
| Year to Date Total Return | -14.50% | |||
| 1-Year Total Return | -69.24% | |||
| 2-Year Total Return | -68.05% | |||
| 3-Year Total Return | -74.21% | |||
| 5-Year Total Return | -73.47% | |||
| 52-Week High % Change | -71.69% | |||
| 52-Week Low % Change | 16.55% | |||
| Price | RGNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $23.14 | |||
| 52-Week Low Price | $5.62 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Mar 21, 2024 | |||
| Valuation | RGNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 324.52M | |||
| Enterprise Value | 221.37M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -5.04 | |||
| Earnings Per Share Growth | -15.94% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3.95 | |||
| Price/Book (Q) | 1.08 | |||
| Enterprise Value/Revenue (TTM) | 2.63 | |||
| Price | $6.72 | |||
| Enterprise Value/EBITDA (TTM) | -0.99 | |||
| Enterprise Value/EBIT | -0.92 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | RGNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 50.80M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | RGNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 240 552 8181 | |||
| Address | 9804 Medical Center Drive Rockville, MD 20850 | |||
| Website | www.regenxbio.com | |||
| Country | United States | |||
| Year Founded | 2008 | |||
| Profitability | RGNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -284.70% | |||
| Profit Margin | -283.18% | |||
| Management Effectiveness | RGNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -26.03% | |||
| Return on Equity | -- | |||
| Income Statement | RGNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 84.33M | |||
| Total Revenue (TTM) | 84.33M | |||
| Revenue Per Share | $1.66 | |||
| Gross Profit (TTM) | -120.81M | |||
| EBITDA (TTM) | -223.55M | |||
| EBIT (TTM) | -240.08M | |||
| Net Income (TTM) | -238.81M | |||
| Net Income Avl. to Common (TTM) | -238.81M | |||
| Total Revenue Growth (Q YOY) | -16.31% | |||
| Earnings Growth (Q YOY) | 3.67% | |||
| EPS Diluted (TTM) | -5.04 | |||
| EPS Diluted Growth (Q YOY) | 16.79% | |||
| Balance Sheet | RGNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 255.46M | |||
| Cash Per Share (Q) | $5.03 | |||
| Total Current Assets (Q) | 313.40M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 301.42M | |||
| Current Ratio (Q) | 3.051 | |||
| Book Value Per Share (Q) | $6.09 | |||
| Total Assets (Q) | 519.11M | |||
| Total Current Liabilities (Q) | 102.73M | |||
| Total Debt (Q) | 145.81M | |||
| Total Liabilities (Q) | 217.70M | |||
| Total Common Equity (Q) | 301.42M | |||
| Cash Flow | RGNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 97.15M | |||
| Cash from Financing (TTM) | 88.46M | |||
| Net Change in Cash (TTM) | 3.35M | |||
| Levered Free Cash Flow (TTM) | -95.26M | |||
| Cash from Operations (TTM) | -182.26M | |||
